UK-US Trade impact on pharmaceutical and chemical sectors examined
17 January 2018
The International Trade Committee continues their inquiry into UK-US trade with a session looking at the impact on pharmaceutical and chemical sectors, and potential consumer benefits.
- Watch Parliament TV: UK-US Trade relations
- Inquiry: UK-US trade relations
- International Trade Committee
Witnesses
Wednesday 17 January, Wilson Room, Portcullis House
At 10am
- Dr Peter Holmes, Reader in Economics, University of Sussex
- Julian Jessop, Chief Economist and Head of the Brexit Unit, Institute for Economic Affairs
- Warwick Lightfoot, Director of Research, and Head of Economics and Social Policy, Policy Exchange
At 11am
- Ian Cranshaw, Head of Business Development and International Trade, Chemical Industries Association
- Howard Chase, Director of Government Affairs, The Dow Chemical Company
- Saoirse Fitzpatrick, Senior Advocacy Adviser, StopAIDS
First session
In this session, the Committee will examine the impact of a free trade deal on consumers. It will assess debates about whether a free trade agreement with the US could allow for cheaper goods and services, alongside debates about the potential effects of a on consumer protections and standards.
Second session
In this session, the Committee will examine how a deal would affect the chemical and pharmaceutical industries. The session will investigate the different approaches to regulation adopted by the US and EU, and ask what approach to regulation would encourage trade in the future. It will also examine the potential effects of the US approach to intellectual property rights on the affordability of medicines.
Further information
Image: iStockphoto